Key Highlights

  • DocGo shares fell 25.11% over one month to $0.2675 as screened on Friday, October 23, 2026.
  • The past week brought a 2.19% decline, with the latest session down 0.96%.
  • Nasdaq extended the $1.00 minimum bid deadline to January 25, 2027.
  • A reverse split of 1-for-5 to 1-for-10 was authorized on June 16, 2026.
  • The pending Hicuity Health deal targets $4.3 million of annual cost savings.

DocGo Stock: Why Did Shares Fall 25.11% in a Month?

DocGo (NASDAQ:DCGO) traded at $0.2675 on Friday, October 23, 2026, down 25.11% over one month and 2.19% over one week, with the latest session down 0.96%. No earnings miss or contract loss is announced for the window. The context is a sub-$1 share price, a pending acquisition and sharply lower revenue.

Health Services, the group the screen places it in, rose 9.54% in the month, so DocGo lagged by about 34.7 percentage points (calculated). It is a penny stock.

Nasdaq Bid Clock: What Happens If the Price Stays Below $1?

On July 28 Nasdaq granted DocGo an additional 180 days, until January 25, 2027, to regain compliance with the $1.00 minimum bid rule. The shares must close at or above $1.00 for at least 10 consecutive business days before then.

Stockholders approved on June 16 a charter amendment allowing a reverse split of 1-for-5 to 1-for-10, with the ratio set by the board. At $0.2675, a 1-for-5 split would lift the quoted price to about $1.34 and a 1-for-10 split to about $2.68 (calculated), so the choice of ratio is the key variable.

A split does not change the market value of a company, and a lower share count can narrow liquidity, so the board is weighing the move against other options. The company said it will monitor the bid price.

Hicuity Health Acquisition: How Does the Deal Fit the Plan?

DocGo provides mobile health and medical transportation services. In late September it held a webinar on the pending acquisition of Hicuity Health, which it described as creating a vertically integrated care platform, with $4.3 million of annual cost savings targeted.

At an investor conference, management said it aims for profitability by year-end. Deal terms and the closing timeline are the open items.

The webinar on the transaction was announced around September 23, and an investor update around September 29 repeated the cost-savings target. Those messages coincide with a falling share price, so investors have not rewarded the deal.

DocGo Financials: Why Does Revenue Matter?

Trailing twelve-month revenue is $294.72 million, down 32.4%, with a net loss of $192.42 million, or $1.96 per share. About 98.93 million shares are outstanding, giving a market value near $26 million at the recent price.

The market value is below one tenth of trailing revenue (calculated), reflecting both the revenue decline and the size of the loss.

What to Watch Next: Will Closing Hicuity and a Reverse Split Come First?

Investors will watch the closing of the Hicuity transaction, the next quarterly report, and any board decision on the reverse split ratio. The January 25, 2027 deadline sets the outer limit for action. Investors will also track progress toward the year-end profitability target.